TransMedics' Organ Care System is driving market share gains by displacing the standard cold storage method for organ preservation. The National OCS Program removes barriers to adoption and improves ...

TransMedics Group (NasdaqGM:TMDX) received full FDA approval for its Next-Generation OCS ENHANCE Heart trial. The decision clears a key regulatory hurdle for the company’s heart-focused organ care ...

TransMedics Group (NASDAQ:TMDX) reported fourth-quarter and full-year 2025 results that management described as the company’s ...

OCS Liver adoption surged, with share of total U.S. liver transplants rising from 26% in 2024 to 36% in 2025. Operating margin expanded from 8.5% in 2024 to 18% in 2025, though guidance for 2026 ...

Add Yahoo as a preferred source to see more of our stories on Google. Part B aims to expand clinical indications for OCS Heart to include standard criteria DBD hearts transplanted within four hours.

ANDOVER, Mass., Aug. 2, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...

ANDOVER, Mass., Feb. 9, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...

TransMedics Group reported impressive first-quarter earnings on May 1, but the stock slipped anyway. TransMedics Group markets an organ-care system that is approved to transport donated hearts, lungs, ...

TransMedics' stock tanked after the company reported third-quarter results. Third-quarter sales rose 64% year over year, but fell slightly compared to the previous quarter. The pullback coincided with ...

TransMedics Group (NASDAQ: TMDX) has emerged as a medical devices industry leader, capturing strong growth and climbing profitability from its organ transplant delivery system. Since the company's ...